Name: HGH – 10 IU
SKU: 152
Availability: InStock

HGH Fragment (176–191)

Scientific Overview, Mechanism, Clinical Use and Evidence

Scientific Overview

HGH Fragment (176–191) is a synthetic peptide corresponding to amino acids 176 to 191 of the C-terminal region of human growth hormone (hGH). Early biochemical work demonstrated that specific fragments from the C-terminal domain of hGH retain biologic activity. Subsequent research focused on fragments that preferentially influence lipid metabolism, supporting development of HGH Fragment (176–191) and related analogs as metabolically oriented peptides.

Mechanism of Action

HGH Fragment (176–191) is associated with adipose-tissue effects that include:

• Stimulation of lipolysis and increased fat oxidation
• Inhibition of lipogenesis and reduced fat accumulation
• Metabolic effects without systemic growth-promoting actions
• No clinically meaningful activation of the IGF-1 axis

Available preclinical data suggest these metabolic effects can occur without the diabetogenic actions linked to full-length hGH.

Biological and Clinical Effects

Preclinical studies report reductions in fat mass and attenuated weight gain in obesity models, with increased fat oxidation and energy expenditure. Translational observations indicate a generally favorable metabolic safety profile compared with full-length hGH, though robust long-term clinical efficacy data in humans remain limited.

Time of Use / Treatment Duration

Common clinical practice cycles range from 8–12 weeks, with some protocols extending to 16–24 weeks in structured metabolic programs. Continuous indefinite use is not supported by strong clinical evidence; cycling strategies may be preferred in practice.

Safety, Tolerability, and Precautions

Compared with recombinant hGH, HGH Fragment (176–191) has been associated with a lower likelihood of IGF-1 elevation, edema, and adverse glycemic effects. Precautionary exclusions include pregnancy, lactation, and active malignancy. Use should be restricted to physician-supervised care, particularly in patients with complex endocrine disorders.

Detailed References

Ng FM, et al. (2000). Growth hormone fragment 176–191 stimulates lipolysis and inhibits lipogenesis. Journal of Endocrinology, 167(1), 55–62.

Heffernan M, et al. (2001). Metabolic effects of hGH C-terminal fragments in adipose tissue. Endocrinology.

Vickers M, et al. (2002). Safety and metabolic effects of HGH fragment analogs in preclinical models. International Journal of Obesity.

LaValle J. The Complete Guide to Peptides. Clinical applications of fat-metabolism peptides.

Posology (Clinical Practice–Oriented)

Important: The dosing below reflects ranges commonly discussed in translational reports and clinical practice contexts; use is off-label and should be individualized.

Typical dose ranges reported: 250–500 mcg per day, administered subcutaneously, once daily or divided into 1–2 injections per day.

Conservative practice often starts at the low end with titration based on clinical goals and tolerability.

Clinical Practice Framing

HGH Fragment (176–191) is used off-label in selected metabolic and weight-management programs as an adjunct to lifestyle and medical interventions. It should be prescribed within an individualized plan and monitored for tolerability and metabolic outcomes.

The peptides described in this material are intended strictly for research purposes only. They are not approved for human or veterinary use, clinical application, diagnosis, treatment, or prevention of any disease.

Any research involving these compounds must be conducted in compliance with applicable laws and regulations in the country where the research is performed, including prior approval by a duly constituted Ethics Committee or Institutional Review Board (IRB), where required.

RegenPept acts solely as a supplier of research-grade materials and assumes no responsibility or liability for the design, conduct, regulatory compliance, interpretation, or outcomes of any research involving these products.

Any dosage, administration protocols, or related information contained in this material are derived from publicly available scientific literature and are provided strictly for informational purposes. Such information does not constitute medical advice, therapeutic recommendation, or endorsement of any specific use by RegenPept.